Aetion has announced a new initiative to help companies across the oncology-related industries better understand the use of real-world evidence (RWE) in regulatory decision-making and clinical trials. The team-up, dubbed the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative. Partners include industry giants, advocacy organizations, universities, and more.
According to PR Newswire, “The Aetion CARE Initiative will focus on better understanding the types of regulatory questions that can be answered using RWE and randomized controlled trials (RCTs), as well as when and why RWE and RCTs might yield the same or different results. The team will conduct multiple trial emulations in various data sources, beginning with a one-year focus on oncology. Using the Aetion Evidence Platform®, the Initiative will help identify when and how RWE can support the goals of advancing efficient access to medication and improving patient care.”
To read more, click here.
(Source: PR Newswire, November 29th, 2022)